Obalon Therapeutics Inc (NQ: OBLN )
5.540 USD -0.480 (-7.97%) Official Closing Price Updated: 7:59 PM EST, Jan 25, 2021 Add to My Watchlist
Press releases about Obalon Therapeutics Inc
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates OBLN, CIT, ZAGG, HLIX; Shareholders Are Encouraged to Contact the Firm
Today 13:19 EST
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Obalon Therapeutics, Inc. Merger
Today 11:30 EST
Lifshitz Law Firm, P.C. Announces Investigation of CHNG, COHR, LITE, CPAH, MGLN, NAV, OBLN, OXFD and WTRE
January 24, 2021
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Obalon Therapeutics, Inc. - OBLN
January 23, 2021
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered...
OBALON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OBLN and Encourages Investors to Contact the Firm
January 22, 2021
ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CHNG, OXFD, SMTX, OBLN, ALXN, BYFC, CIT
January 22, 2021
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
OBALON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Obalon Therapeutics, Inc. - OBLN
January 22, 2021
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Obalon Therapeutics, Inc. (NasdaqGS: OBLN)...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ: OBLN) in...
Obalon Announces Third Quarter 2020 Financial Results
November 06, 2020
Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System
August 13, 2020
Obalon Announces Second Quarter 2020 Financial Results
July 30, 2020
Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment
May 11, 2020
William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director
May 08, 2020
Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons
April 28, 2020
Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA
Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic
March 17, 2020
No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority
Obalon Announces Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020
Obalon Enters into a Distribution Agreement for Qatar
December 18, 2019
Spindletop Capital Management, a healthcare-focused growth equity firm, is pleased to announce the promotion of Kelly Huang, Ph.D. as a Managing Director of Spindletop Capital. The promotion was in...
Obalon Announces Third Quarter 2019 Financial Results
November 08, 2019
San Diego, CA -- (SBWIRE) -- 10/07/2019 -- An investor in Obalon Therapeutics Inc (NASDAQ: OBLN) filed a lawsuit against Obalon Therapeutics Inc (NASDAQ: OBLN) over alleged securities laws violations.
Obalon (OBLN) Alert: Johnson Fistel Announces Shareholder Class Action Against Obalon Therapeutics Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?
September 28, 2019
Johnson Fistel, LLP is investigating potential claims on behalf of Obalon Therapeutics, Inc. (NASDAQ: OBLN) ("Obalon" or the "Company") against certain of its officers and directors.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Obalon Therapeutics, Inc. – OBLN
July 24, 2019
Levi & Korsinsky announces it has commenced an investigation of Obalon Therapeutics, Inc. (NASDAQ: OBLN) concerning possible breaches of fiduciary duty. To obtain additional information, go to:
Obalon Announces Second Quarter 2019 Financial Results
July 24, 2019
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of...
Obalon Appoints Bob MacDonald as Chief Retail Officer
June 10, 2019
Experienced executive with successful track record of leading strategic growth initiatives, including national chain of retail cosmetic surgery clinics